- Home
- RYTM vs VIST Comparison
RYTM vs VIST Comparison
Compare RYTM & VIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RYTM | VIST |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | Mexico |
| Employees | N/A | 584 |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.7B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | RYTM | VIST |
|---|---|---|
| Price | $105.64 | $63.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 3 |
| Target Price | ★ $131.14 | $81.33 |
| AVG Volume (30 Days) | ★ 872.9K | 843.6K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.34 | $20.93 |
| Revenue Next Year | $86.06 | $20.35 |
| P/E Ratio | ★ N/A | $7.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $74.50 | $33.37 |
| 52 Week High | $122.20 | $81.44 |
Technical Indicators
Market Signals| Indicator | RYTM | VIST |
|---|---|---|
| Relative Strength Index (RSI) | 53.92 | 42.61 |
| Support Level | $98.30 | $61.25 |
| Resistance Level | $113.51 | $77.59 |
| Average True Range (ATR) | 4.38 | 2.29 |
| MACD | -1.22 | 0.29 |
| Stochastic Oscillator | 21.67 | 49.80 |
Price Performance
Historical ComparisonAbout RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
About VIST Vista Energy S.A.B. de C.V. each representing one series A share with no par value
Vista Energy SAB de CV is an independent oil and gas company. It is focused on shale oil and shale gas exploration at its main assets in Vaca Muerta. The company has operations in Argentina and Mexico. The company operates in a single segment- the exploration and production of Crude oil, Natural gas, and LPG. Geographically, it operates in Argentina and Mexico. Product-wise, the firm generates the majority of its revenue from crude oil sales, natural gas sales, and LPG sales.